ACADIA Pharmaceuticals(us:ACAD)

16.32

-1.75%

Updated on 2025-04-02

Open:16.56
Close:16.32
High:16.77
Low:16.15
Prev Close:16.61
Volume:2.61M
Turnover:42.75M
Turnover Ratio:1.57%
Shares:166.79M
MarketCap:2.72B
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-3029616072675196.91%37110115
2024-03-3131615967216896.79%48100131
2023-12-3130215935377596.78%59102101
2023-09-3026915491471894.48%399199
2023-06-3026115757900796.46%3376107
2023-03-3125415509104495.51%367495
2022-12-3124615567131996.06%2973102
2022-09-3026415025210592.82%2279114
dateorgNametotalratiochangeShareschangeRatio
2024-06-30Baker Bros. Advisors Lp4287791625.85%133040.03%
2024-06-30Vanguard Group Inc137121318.27%4135903.11%
2024-06-30Rtw Investments, Lp137075068.26%-121809-0.88%
2024-06-30Blackrock Inc.120622137.27%3934733.37%
2024-06-30State Street Corp58007903.50%-200613-3.34%
2024-06-30Point72 Asset Management, L.P.37101402.24%2933440377.68%
2024-06-30Millennium Management Llc29377141.77%83237039.54%
2024-06-30D. E. Shaw & Co., Inc.29349261.77%29290611.09%
2024-06-30Geode Capital Management, Llc28447141.72%514771.84%
2024-06-30Marshall Wace, Llp27743531.67%2251940431.06%

About

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Address:12830 El Camino Real,Suite 400

Market Movers